GGiantBullStocks

Esperion Therapeutics, Inc. (ESPR)

NASDAQ · Healthcare

$3.180.00%

As of Jul 13, 2026

Price history

Key statistics

Market cap
$663.23M
P/E ratio
EPS
Volume
0
52-week high
$4.18
52-week low
$1.10
Open
$3.18
Day high
$3.18
Day low
$3.18

Financial highlights

Fiscal yearRevenueNet incomeEPS
2025$403.14M-$22.68M-$0.11
2024$332.31M-$51.75M-$0.28
2023$116.33M-$209.25M-$2.03
2022$75.48M-$233.66M-$3.52
2021$78.45M-$269.11M-$9.31

About Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc. operates as a pharmaceutical firm, concentrating on the development and commercialization of treatments for individuals with high levels of low-density lipoprotein (LDL) cholesterol. The company's flagship pharmaceutical products are NEXLETOL (bempedoic acid) and NEXLIZET (a tablet combining bempedoic acid and ezetimibe), prescribed for managing conditions such as atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. In addition, Esperion maintains a licensing and collaborative partnership with Daiichi Sankyo Europe GmbH, alongside an agreement with Serometrix to acquire rights to an oral, small molecule PCSK9 inhibitor program. Established in 2008, the company's corporate offices are situated in Ann Arbor, Michigan.

CEO
Sheldon L. Koenig
Employees
304
Country
US
IPO date
Jun 26, 2013

Similar stocks

Other Healthcare companies

Frequently asked questions

What is Esperion Therapeutics, Inc.'s stock price today?
ESPR is trading at $3.18 as of Jul 13, 2026.
What is Esperion Therapeutics, Inc.'s market cap?
Esperion Therapeutics, Inc. (ESPR) has a market capitalization of $663.23M.
What is ESPR's 52-week range?
Over the past 52 weeks, ESPR has traded between $1.10 and $4.18.
Does Esperion Therapeutics, Inc. pay a dividend?
Esperion Therapeutics, Inc. did not pay a dividend in its most recent reported fiscal year.
What sector is Esperion Therapeutics, Inc. in?
Esperion Therapeutics, Inc. operates in the Healthcare sector.